Inspire: Azasite doesn't meet goals in trials

North Carolina-based Inspire Pharmaceuticals announced this morning that Azasite, a drug already approved to treat conjunctivitis, failed to reach the main endpoint in two Phase II clinical trials evaluating it in blepharitis patients. The company says it will conduct additional work to refine trial parameters for an anticipated Phase III program. Inspire's release

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.